Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Opioid Crisis Lawsuits
Pharma

Ex-CEO is first drug exec indicted in opioid crisis

By Associated Press

Pharmalot

Biotechs account for more of the industry pipeline, even as big pharma spends more on R&D

By Ed Silverman

Pharmalot

Pharmalittle: PBMs set new record for lobbying spending; insurer sues J&J over ‘sham’ patent litigation

By Ed Silverman

White pills on yellow background
Pharmalot

In possible blueprint for other states, Ohio attorney general floats proposals to rein in PBMs

By Ed Silverman

Pharmalot
Pharmalot

Insurer accuses J&J unit of using ‘sham’ patent litigation to extend monopoly on cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: Novartis probes second death in gene therapy trial; FDA approves generic Narcan

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices

By Ed Silverman

Speaking to scientists
Pharmalot

Maine seeks to clarify limits on gifts and payments that pharma can give doctors

By Ed Silverman

Hepatitis Drugs
Pharmalot

Chilean minister pushes back against pharma move to pressure its pricing policies

By Ed Silverman

Prescription Medication
Pharmalot

Pricing is taking a toll on the reputation of the pharmaceutical industry

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi pledge to rebuild Notre Dame gets backlash; IBM halts AI product for drug development

By Ed Silverman

IBM logo
Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

By Casey Ross

Pharmalot

Pharmalittle: Stronger warnings urged for Amgen’s osteoporosis drug; prices in drug ads can be jarring

By Ed Silverman and Elizabeth Cooney

Pharmalot

Judge slams Justice Department bid to dismiss a nurse educator lawsuit

By Ed Silverman

Xarelto
Pharmalot

A first-of-its-kind law in Tennessee limits lawyers’ ads seeking to sue drug makers

By Ed Silverman

Pharmalot

Pharmalittle: Look who’s advising Nancy Pelosi on drug prices; Purdue tried to buy an opioid-addiction treatment business

By Ed Silverman

STAT PLUS - Janet Woodcock
Pharmalot

FDA’s Woodcock on developing neuromuscular drugs: ‘We have to change our approach’

By Ed Silverman

Blurry doctors
Pharmalot

A database that reveals industry payments to doctors also causes patient mistrust

By Ed Silverman

Pharmalot

Supreme Court rejects Allergan bid to use a Native American tribe to shield important patents

By Ed Silverman

Pharmalot

Pharmalittle: J&J gets U.S. nod for first targeted bladder cancer drug; Allergan wins key support from advisory firms

By Ed Silverman

JUST MERGERED
Pharma

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

By Damian Garde and Adam Feuerstein

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Many employers want to eliminate rebates; Gilead takes another run at NASH

By Ed Silverman

Pharmalot

FDA chastises maker of the Addyi female libido pill over trying to remove alcohol safety warning

By Ed Silverman

Medical costs
Pharmalot

Many employers would like to eliminate those controversial rebates on drugs

By Ed Silverman

Chuck Grassley, Ron Wyden
Pharmalot

Lawmakers ask the Trump administration to investigate PBM pricing practices

By Ed Silverman

Pharmalot

Pharmalittle: Hearing on insulin prices leaves lawmakers frustrated; House committee passes drug transparency bill

By Ed Silverman

HIV prevention pill Truvada
Pharmalot

AIDS activists skewer CDC for conflicting stance on collecting HIV drug royalties

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy